Cross-immunity against SARS-COV-2 variants of concern in naturally infected critically ill COVID-19 patients-Reference-Cited by-同舟云学术

Cross-immunity against SARS-COV-2 variants of concern in naturally infected critically ill COVID-19 patients

Published:2023-01 Issue:1 Volume:9 Page:e12704
ISSN:2405-8440
Container-title:Heliyon
language:en
Short-container-title:Heliyon

Author:

Fraser Douglas D.^ORCID,Patel Maitray A.^ORCID,Van Nynatten Logan R.,Martin Claudio^ORCID,Seney Shannon L.^ORCID,Miller Michael R.,Daley Mark^ORCID,Slessarev Marat^ORCID,Cepinskas Gediminas^ORCID,Juneja Ganeem K.,Sabourin Vanessa,Fox-Robichaud Alison,Yeh Calvin H.,Kim Paul Y.^ORCID,Badrnya Sigrun,Oehler Susanne,Miholits Markus,Webb Brian

Funder

Department of Medicine, Georgetown University

Lawson Health Research Institute

London Health Sciences Foundation

Academic Medical Organization of Southwestern Ontario

Canadian Institutes of Health Research

Western University

London Community Foundation

Publisher

Elsevier BV

Subject

Multidisciplinary

Reference58 articles.

1. Outcomes from intensive care in patients with COVID-19: a systematic review and meta-analysis of observational studies;Armstrong;Anaesthesia,2020

2. Innate immune response to viral infection;Koyama;Cytokine,2008

3. COVID-19 plasma proteome reveals novel temporal and cell-specific signatures for disease severity and high-precision disease management;Iosef;J. Cell Mol. Med.,2022

4. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm;Garvin;Elife,2020

5. Inflammation profiling of critically ill coronavirus disease 2019 patients;Fraser;Crit. Care Explor.,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association Between ACE2 and Lung Diseases;Infection and Drug Resistance;2024-05

2. Evaluation of Mutual Information and Feature Selection for SARS-CoV-2 Respiratory Infection;Bioengineering;2023-07-24

3. Variable neutralizing antibody responses to 10 SARS-CoV-2 variants in natural infection with wild- type (B.1) virus, Kappa (B.1.617.1), and Delta (B.1.617.2) variants and COVISHIELD vaccine immunization in India: utility of the MSD platform;Frontiers in Immunology;2023-06-05